

## [NVP01201506 Afinitor \(everolimus\)](#)

### Welcome & intro

Doctors.net.uk invites you to participate in a survey commissioned by a pharmaceutical company concerning **the treatment of cancer**. The survey will take around 5 minutes to complete and all eligible members completing the survey will receive 1,500 eSR points. Please read the following text, which explains the intent of this research.

Doctors.net.uk would like to reassure you that:

- Doctors.net.uk will comply with all UK laws protecting your personal data and the British Healthcare Business Intelligence Association / Market Research Society guidelines.
- Your responses will be used by us and the sponsoring pharmaceutical company for market research purposes only.
- Your responses will be collated with other respondents and presented to the sponsor in aggregated or anonymised form.
- Doctors.net.uk are now being asked to pass on to our client details of adverse events that are raised during the course of market research interviews. Although this is an online market research interview and how you respond will, of course, be treated in confidence, should you raise an adverse event in a specific patient, Doctors.net.uk will need to report this, even if it has already been reported by you directly to the company or the regulatory authorities using the MHRA's "Yellow Card" system.
- In such a situation you will be asked whether or not you are willing to waive the confidentiality given to you under the Market Research Codes of Conduct specifically and only in relation to that adverse event. Everything else you contribute during the course of the interview will continue to remain confidential, and you will still have the option to remain anonymous if you so wish.
- Your responses will be otherwise confidential and will not be used for any other purposes or disclosed to any third party without your approval.

Please confirm that you have read and understood this information

Yes

No

*Close if No*

***NB: Respondents must answer ALL screening questions before being screened in or out***

### **S1 Speciality**

What is your primary responsibility?

*Drop down list of all specialities*

*Single response; CONTINUE if Oncology selected, otherwise CLOSE*

*Validate against DNUK profile*

### **S2 Seniority**

Please select your seniority:

Consultant

Associate Specialist  
Staff Grade  
Specialty Registrar (year 5+)  
Specialty Registrar (year 3-4)  
Specialty Registrar (year 1-2)  
Other

*Single response; recruit to Quota (set quotas as 50:50 Consultant:SpR but want to maximise Consultants); CLOSE if SpR 1-2, 3-4 or Other*

### **S3 SHA**

Where are you currently practising?

North West SHA  
North East SHA  
Yorkshire / Humber SHA  
East Midlands SHA  
West Midlands SHA  
East of England SHA  
London SHA  
South East Coast SHA  
South Central SHA  
South West SHA  
Scotland  
Wales  
Northern Ireland  
Outside UK  
Retired

*Single response; CLOSE if 'outside UK' or 'retired'*

### **S4 Centre**

Is your centre ...

A DGH  
A teaching hospital  
A tertiary centre  
A private practice  
Other (please specify)

*Single response*

### **S5 Cancer Specialities**

Which of the following types of cancer do you treat?

*Please select those which most apply (you can select more than one answer)*

Anal cancer  
Bladder cancer

Bone tumours  
Brain tumours  
Breast cancer  
Cancer of the cervix  
Cancer of the pancreas  
Colon and rectal cancer  
Head and neck cancer  
Hepatocellular carcinoma  
Hodgkin's disease  
Kidney cancer  
Lung cancer  
Melanoma  
Myeloma and plasmacytoma  
Non Hodgkin's lymphoma  
Oesophageal cancer  
Ovarian cancer  
Prostate cancer  
Soft tissue sarcoma  
Stomach cancer (gastric cancer)  
Testis cancer  
Thyroid cancer  
Uterine cancer  
All other (non specified)

*Multi response; CONTINUE if 'kidney cancer' selected, otherwise CLOSE*

## **S6 Patient Types Treated**

In relation to the kidney cancer patients you treat, please estimate how many patients you have treated in the following stages in the last 12 months.

*Please enter the number of patients you have treated in the following stages in the last 12 months*

Stage I (cancer less than 7cm across and completely inside the kidney)

Stage II (cancer is more than 7cm across but still completely inside the kidney)

Stage III (cancer has grown into adrenal gland, or one of the major veins nearby; there is no more than one nearby lymph node containing cancer cells)

Stage IV (cancer has grown into surrounding tissues and there is more than one lymph node containing cancer cells OR the cancer has spread to another part of the body)

*Multi response*

*CLOSE if <10 patients entered for Stage IV*

**The remainder of this survey is about Stage IV kidney cancer (advanced and / or metastatic renal cell carcinoma), specifically those patients who have failed 1<sup>st</sup> line therapy.**

## **Q1 Survival Duration (Bandings)**

In your experience of treating metastatic renal cell carcinoma, how long on average would you expect a patient to survive after failing 1<sup>st</sup> line therapy with sunitinib (Sutent) if left untreated?

*Please select one answer from the list below:*

- 0-5 months
- 6-9 months
- 10-12 months
- 12+ months

*Single response*

*ASK IF Q1\_1, Q1\_2, Q1\_3, Q1\_4 selected (if Q1\_5 selected, GO TO Q3)*

### **Q2 Survival Duration (Numeric)**

In your experience of treating metastatic renal cell carcinoma, how long on average would you expect a patient to survive after failing 1<sup>st</sup> line therapy with sunitinib (Sutent) if left untreated?

*Please use the sliding scale below to select the most likely survival duration in months*

*Sliding scale (min = 0, max = 12, increments of 1)*

### **D1 Gender**

Please select your gender:

- Male
- Female

*Single response*

### **D2 Age**

Are you ...

- 30 years or under
- 31-40
- 41-50
- 51-60
- 61+

*Single response*

**THANK & CLOSE**